Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Effectiveness of interdisciplinary vs. dermatological care of moderate-to-severe psoriasis: a pragmatic randomised controlled trial.

Schmitt J, Wozel G, Garzarolli M, Viehweg A, Bauer M, Leopold K.

Acta Derm Venereol. 2014 Mar;94(2):192-7. doi: 10.2340/00015555-1697.

2.

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.

Mattei PL, Corey KC, Kimball AB.

J Eur Acad Dermatol Venereol. 2014 Mar;28(3):333-7. doi: 10.1111/jdv.12106. Epub 2013 Feb 21. Review.

PMID:
23425140
3.

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres.

Balogh O, Brodszky V, Gulácsi L, Herédi E, Herszényi K, Jókai H, Kárpáti S, Baji P, Remenyik É, Szegedi A, Holló P.

Eur J Health Econ. 2014 May;15 Suppl 1:S101-9. doi: 10.1007/s10198-014-0599-z. Epub 2014 May 16.

PMID:
24832841
4.

Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study.

Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, Reich K.

J Dtsch Dermatol Ges. 2007 Mar;5(3):209-18. English, German.

PMID:
17338796
5.

Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.

Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI; PEARL investigators.

J Drugs Dermatol. 2012 Aug;11(8):943-9.

PMID:
22859239
6.

Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.

Dermatology. 2008;216(3):260-70. doi: 10.1159/000113150. Epub 2008 Jan 11.

PMID:
18187944
7.

Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.

Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M.

Br J Dermatol. 2012 Apr;166(4):797-802. doi: 10.1111/j.1365-2133.2011.10778.x. Epub 2012 Mar 12.

PMID:
22182212
8.

Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.

Spuls PI, Hooft L.

Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. doi: 10.1111/bjd.12025.

PMID:
23013312
9.

Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).

Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):452-6. doi: 10.1111/jdv.12576. Epub 2014 Jun 9.

PMID:
24911993
10.

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.

Br J Dermatol. 2005 May;152(5):954-60.

PMID:
15888152
11.

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG.

Br J Dermatol. 2010 Jan;162(1):137-46. doi: 10.1111/j.1365-2133.2009.09491.x. Epub 2009 Nov 9.

PMID:
19903183
12.

Definition of treatment goals for moderate to severe psoriasis: a European consensus.

Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N.

Arch Dermatol Res. 2011 Jan;303(1):1-10. doi: 10.1007/s00403-010-1080-1. Epub 2010 Sep 21.

13.

Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis.

Consoli SM, Rolhion S, Martin C, Ruel K, Cambazard F, Pellet J, Misery L.

Dermatology. 2006;212(2):128-36.

PMID:
16484819
14.

Quality of psoriasis care in Germany--results of the national study PsoHealth 2007.

Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Schäfer I, Radtke M.

J Dtsch Dermatol Ges. 2008 Aug;6(8):640-5. doi: 10.1111/j.1610-0387.2008.06807.x. English, German.

PMID:
18801145
15.

Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.

Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.

J Drugs Dermatol. 2013 Aug;12(8):874-80.

PMID:
23986160
16.

The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.

Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.

Health Qual Life Outcomes. 2006 Sep 27;4:71.

17.

Quality of psoriasis care in Germany: results of the national health care study "PsoHealth3".

Langenbruch A, Radtke MA, Jacobi A, Purwins S, Haack K, Reich K, Stroemer K, Mrowietz U, Augustin M.

Arch Dermatol Res. 2016 Aug;308(6):401-8. doi: 10.1007/s00403-016-1651-x. Epub 2016 May 20.

PMID:
27206971
18.

Psoriasis affects patient's quality of life more seriously in female than in male in Japan.

Mabuchi T, Yamaoka H, Kojima T, Ikoma N, Akasaka E, Ozawa A.

Tokai J Exp Clin Med. 2012 Sep 20;37(3):84-8.

19.

Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study.

Daudén E, Herrera E, Puig L, Sánchez-Carazo JL, Toribio J, Perulero N.

Actas Dermosifiliogr. 2013 Oct;104(8):685-93. doi: 10.1016/j.adengl.2013.02.008. Epub 2013 Aug 16.

PMID:
23958428
20.

Health-related quality of life in psoriasis: an analysis of Psocare project patients.

Spandonaro F, Altomare G, Berardesca E, Calzavara-Pinton P, Chimenti S, Girolomoni G, Peserico A, Guerra AP, Vena GA, Polistena B, Ayala F.

G Ital Dermatol Venereol. 2011 Jun;146(3):169-77.

PMID:
21566546

Supplemental Content

Support Center